Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Idorsia Pharmaceuticals Ltd.
Age
12–76
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females aged 12-76 years with documented clinical history of symptomatic seasonal allergic rhinitis associated with mountain cedar pollen for the last 2 years.
Evening reflective Total Nasal Symptom Score (p.m.rTNSS) at least 42 out of a maximum potential score of 84 over the 7-day run-in period, or \> or = 6 out of a maximum score of 12 on each of the last 4 consecutive days during the run-in period.
You may not be if
Non-allergic rhinitis.
Severe physical nasal obstruction.
Acute or significant chronic sinusitis.
Bacterial or viral infection of the upper or lower respiratory tract, nasal sinuses, or middle ear.
Ongoing chronic respiratory disorders.
Asthma requiring use of short-acting beta2-agonists \> 2 times a week or any asthma treatment other than inhaled short-acting beta2-agonists.
Diagnosis of aspirin or non-steroidal anti-inflammatory drug (NSAID)-induced asthma.
Nasal biopsy or surgery, sinus surgery, or perforation within the 8 weeks prior to the Screening Visit.
Ocular surgery within the 8 weeks prior to the Screening Visit.
Ocular infections (bacterial or viral) within the 4 weeks before screening.
Use of forbidden medications (prescribed or over-the-counter \[OTC\])
Congenital or acquired severe immunodeficiency or known Human immunodeficiency virus (HIV)infection.
Clareo Health | Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis
